HSF1 and prostate carcinoma: NCI-H660 was selected to evaluate the effect of targeting HSF1 and CBS because we have previously shown that less aggressive in vivo models of prostate cancer including C4-2, 22Rv1, and TRAMP-C2 have a strong response to HSF1 inhibition alone14.